ArticleAdvanced functional materials2017
MUC1 Aptamer Targeted SERS Nanoprobes.
Article in Advanced functional materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Raman and surface-enhanced Raman spectroscopy for intraoperative cancer diagnostics: sentinel lymph node biopsy, biomarkers and translational challenges.Frontiers in bioengineering and biotechnology · 2026Review
- Surface-Enhanced Raman Spectroscopy (SERS) Based Biological and Environmental 2D and 3D Imaging.ACS environmental Au · 2025Review
- The Application of Aptamer and Research Progress in Liver Disease.Molecular biotechnology · 2024Review
- Development of aptamer surface-enhanced Raman spectroscopy sensor based on FeMikrochimica acta · 2024Article
- Simultaneous subset tracing and miRNA profiling of tumor-derived exosomes via dual-surface-protein orthogonal barcoding.Science advances · 2023Article
- Challenges and opportunities for SERS in the infrared: materials and methods.Nanoscale advances · 2023Review
- Design and Synthesis of SERS Materials for In Vivo Molecular Imaging and Biosensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate.Biomaterials research · 2022Article
- Design and evaluation of Raman reporters for the Raman-silent region.Nanotheranostics · 2022Article
- Design and synthesis of gold nanostars-based SERS nanotags for bioimaging applications.Nanotheranostics · 2022Review
- SERS Tags for Biomedical Detection and Bioimaging.Theranostics · 2022Review
- Aptamers used for molecular imaging and theranostics - recent developments.Theranostics · 2022Review
- Size-Dependent Penetration of Gold Nanoprobes into Fixed Cells.ACS omega · 2021Article
- Spatially offset Raman spectroscopy for biomedical applications.Chemical Society reviews · 2021Review
- The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).Theranostics · 2021Review
- DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Extracellular Vesicle Identification Using Label-Free Surface-Enhanced Raman Spectroscopy: Detection and Signal Analysis Strategies.Molecules (Basel, Switzerland) · 2020Review
- Present and Future of Surface-Enhanced Raman Scattering.ACS nano · 2020Article
- Nondestructive analysis of tumor-associated membrane protein MUC1 in living cells based on dual-terminal amplification of a DNA ternary complex.Theranostics · 2020Article
- Active targeting drug-gold nanorod hybrid nanoparticles for amplifying photoacoustic signal and enhancing anticancer efficacy.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recently, surface-enhanced Raman scattering (SERS) nanoprobes (NPs) have shown promise in the field of cancer imaging due to their unparalleled signal specificity and high sensitivity. Here we report the development of a DNA aptamer targeted SERS NP. Recently, aptamers are being investigated as a viable alternative to more traditional antibody targeting due to their low immunogenicity and low cost of production. We developed a strategy to functionalize SERS NPs with DNA aptamers, which target Mucin1 (MUC1) in human breast cancer (BC). Thorough in vitro characterization studies demonstrated excellent serum stability and specific binding of the targeted NPs to MUC1. In order to test their
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.